A new generation of vaccines within animal health

Intervacc AB is a Swedish company active in the biotechnology sector. We develop new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile.

Strangvac - our strangles vaccine projectINV274 a vaccine candidate against infections caused by Strep suis INV412 a vaccine candidate against mastitis caused by Staph aureus

Together with our two subsidiaries Nordvacc Läkemedel and the Mybac-Vettech Laboratory, we strive to strengthen animal health and welfare. Here you can find more about the Group’s products and services and our vaccine candidate against equine strangles, Strangvac ®, the first of the new generation of vaccines.

  • Intervacc’s subsidiary company Nordvacc have over 30 years’ experience in the veterinary vaccines market, serving the Nordic, Dutch and Baltic markets with more than 200 million doses sold
  • The technology platform is based on research from the Karolinska Institute and the Swedish University of Agricultural Sciences
  • Strangles

    a highly contagious infectious horse disease lacking adequate vaccine protection

ABGSC Investor Days

Intervacc participated in ABGSC Investor Day on March 19, 2020 in Stockholm. CEO Andreas Andersson presented the company and the development of a new generation of animal health vaccines. The focus was on Strangvac® and the by EMA recently, confirmed application for marketing authorization which is now validated and ready for review.

Here you can see the recorded presentation which is about 24 minutes including the following Q&A.